



Notification HUM-6812:

Category

HCPCS - Drugs & Biologicals

Topic

Infliximab and its biosimilars

What is changing? / Change Description:

We apply the following limitations to charges for HCPCS codes J1745, Q5103, Q5104, Q5109 and Q5121 if billed by a specialty of pharmacy with a diagnosis of juvenile idiopathic arthritis:

- No more than 630 units every 26 weeks for patients between 2 and 5.**
- No more than 962 units every 26 weeks for patients between 5 and 8.**
- No more than 1,449 units every 26 weeks for patients between 8 and 11.**
- No More than 2151 units every 26 weeks for patients between 11 and 15.**
- No more than 2,522 units every 26 weeks for patients 15 and older.**

Language

English

Impacted Products

Medicaid – Louisiana

Why is Humana making this change? / Change Reason:

The limitations above are established by the FDA-approved package insert and prescribing information and the pharmaceutical compendia.

Note: The limitations described above are based on maximum dosages established in milligrams. If any units are denied, the provider may dispute the decision through the appropriate process. The provider may submit information, including medical notes showing the patient's body weight, that substantiates the medical necessity of the additional units.